PCM
CALA

Piermont Capital Management’s Calithera Biosciences, Inc CALA Stock Holding History

Piermont Capital Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,920
Closed -$192K – 229
2018
Q2 		$192K Buy
+1,920
New +$218K 0.06% 232

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piermont Capital Management's CALA Position: Q3 2018 in Review

Piermont Capital Management sold out of Calithera Biosciences, Inc (CALA) in Q3 2018, closing a stake of 1,920 shares — an estimated $192K sold.

Piermont Capital Management first reported a position in CALA in Q2 2018 and held it in 1 quarter. The position peaked at $192K in Q2 2018. 81 funds tracked by Wall St. Rank hold CALA as of Q3 2018.

  • Piermont Capital Management reported no remaining Calithera Biosciences, Inc position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 1,920 Calithera Biosciences, Inc shares in Q3 2018, an estimated $192K.
  • Piermont Capital Management first reported a position in Calithera Biosciences, Inc in Q2 2018 and held it in 1 quarter.
  • Piermont Capital Management's Calithera Biosciences, Inc position peaked at $192K in Q2 2018.
  • 81 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.